InChI=1S/C30H42O7/c1-15(10-17(31)11-16(2)26(36)37)18-12-23(35)30(7)25-19(32)13-21-27(3,4)22(34)8-9-28(21,5)24(25)20(33)14-29(18,30)6/h15-16,18-19,21,32H,8-14H2,1-7H3,(H,36,37)/t15-,16-,18-,19+,21+,28+,29-,30+/m1/s1

Ganoderic acid C1(GAC1), isolated from the ganoderma mushroom, has cytotoxicity in vitro against Lewis lung carcinoma (LLC), T-47D, Sarcoma 180, and Meth-A tumor cell lines. [1]
Ganoderic acid C1 significantly reduces TNF-α production by murine macrophages (RAW 264.7 cells) and peripheral blood mononuclear cells (PBMCs) from asthma patients; inhibition is associated with down-regulation of NF-κB expression, and partial suppression of MAPK and AP-1 signaling pathways; suggests that GAC1 may have potential for treating TNF-α mediated inflammation in asthma and other inflammatory diseases. [2]
Ganoderic acid C1 is moderately active inhibitors against HIV-1 PR with a 50% inhibitory concentration of 0.17–0.23mM. [3]
Ganoderic acid C1 can inhibit TNF-α production in RW-stimulated RAW264.7 cells in association with suppression of phosphorylated IκB and increas HDAC2 expression, GAC1 may be a valuable option for treating neutrophil-predominant asthma.  [4]

English website: Ganoderic acid C1
Japanese website: Ganoderic acid C1
Chinese website: Ganoderic acid C1

[1] Gao J J, Min B S, Ahn E M, et al. Chem Pharml Bull, 2002, 50(6):837-40.
[2] Liu C, Nan Y, Ying S, et al. Int Immunopharmacol, 2015, 27(2):1556-8.
[3] El-Mekkawy S, Meselhy M R, Nakamura N, et al. Phytochemistry, 1998, 49(6):1651-7.
[4] Srivastava K D, Dunkin D, Liu C, et al. Ann Aller Asthma Im, 2014, 112(4):1-2.
[5] B M Li,  Gu HF, L i Y, et al. China Journal of Chinese Materia Medica, 2012, 37(23):3599-603.